General Group Discussion — Problems in Study Design

  • Joel Morganroth
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 18)


Dr. Sami: My question is for Dr. Temple. I am a Canadian and not really involved with the F.D.A.; but if you were presented with a drug, let’s say a beta blocker, which had identical action to propranolol and identical side effects, identical efficacy in every respect, would that make a problem in approving this drug for clinical use or not?


Placebo Toxicity Ischemia Europe Expense 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Martinus Nijhoff Publishers, The Hague 1982

Authors and Affiliations

  • Joel Morganroth

There are no affiliations available

Personalised recommendations